- Home
- SACH vs IKNA Comparison
SACH vs IKNA Comparison
Compare SACH & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SACH
- IKNA
- Stock Information
- Founded
- SACH 2010
- IKNA 2016
- Country
- SACH United States
- IKNA United States
- Employees
- SACH N/A
- IKNA N/A
- Industry
- SACH Real Estate Investment Trusts
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- SACH Real Estate
- IKNA Health Care
- Exchange
- SACH Nasdaq
- IKNA Nasdaq
- Market Cap
- SACH 46.2M
- IKNA 52.1M
- IPO Year
- SACH 2017
- IKNA 2021
- Fundamental
- Price
- SACH $0.99
- IKNA $1.19
- Analyst Decision
- SACH Hold
- IKNA Buy
- Analyst Count
- SACH 3
- IKNA 2
- Target Price
- SACH $2.25
- IKNA $3.00
- AVG Volume (30 Days)
- SACH 287.2K
- IKNA 108.0K
- Earning Date
- SACH 05-01-2025
- IKNA 05-08-2025
- Dividend Yield
- SACH 18.24%
- IKNA N/A
- EPS Growth
- SACH N/A
- IKNA N/A
- EPS
- SACH N/A
- IKNA N/A
- Revenue
- SACH N/A
- IKNA N/A
- Revenue This Year
- SACH N/A
- IKNA N/A
- Revenue Next Year
- SACH $4.52
- IKNA N/A
- P/E Ratio
- SACH N/A
- IKNA N/A
- Revenue Growth
- SACH N/A
- IKNA N/A
- 52 Week Low
- SACH $0.80
- IKNA $0.97
- 52 Week High
- SACH $3.16
- IKNA $1.94
- Technical
- Relative Strength Index (RSI)
- SACH 52.18
- IKNA 53.94
- Support Level
- SACH $0.90
- IKNA $1.10
- Resistance Level
- SACH $0.98
- IKNA $1.20
- Average True Range (ATR)
- SACH 0.05
- IKNA 0.08
- MACD
- SACH 0.01
- IKNA 0.01
- Stochastic Oscillator
- SACH 93.37
- IKNA 74.26
About SACH Sachem Capital Corp.
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.